ABBV Stock Risk & Deep Value Analysis
AbbVie Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
The Bottom Line on ABBV
We analyzed AbbVie Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABBV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈ABBV Performance Overview3yr weekly
Unlock ABBV Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ABBV Stock Risk Analysis
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
About AbbVie Inc (ABBV)
Sector
Healthcare
Industry
Drug Manufacturers - General
Market Cap Category
mega
Market Cap
$403.83B
ABBV Deep Value Analysis
ABBV Red Flags & Warning Signs
Premium- ⚠
Greater-than-expected erosion from Humira biosimilar competition (ongoing)
- ⚠
Pipeline failures or significant delays in key clinical trials
- ⚠
Negative regulatory decisions or unexpected hurdles for new drug approvals
- ⚠
Increased pricing pressure from governments or payers on existing or new drugs
Unlock ABBV Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
ABBV Financial Health Metrics
Market Cap
$403.83B
P/E Ratio
171.80
ABBV Competitive Moat Analysis
PremiumMoat Rating
Wide
Moat Trend
Stable
Moat Sources
4 Identified
AbbVie's wide moat is primarily driven by its extensive and continuously replenished portfolio of patented blockbuster drugs, particularly in immunology and oncology. High R&D investment and regulatory hurdles protect these assets, creating significant switching costs for patients and providers. While patent expirations (like Humira's) present challenges, the company's robust pipeline and strategic M&A consistently introduce new proprietary assets to maintain its competitive edge over a 20+ year horizon.
ABBV Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
ABBV Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April 2026)
- •Updates on regulatory filings for new indications for Skyrizi and Rinvoq (e.g., ulcerative colitis, Crohn's disease expansion)
- •Presentation of Phase 3 data for select early-stage pipeline assets (e.g., oncology, neuroscience)
Medium-Term (6-18 months)
- •Launch of new product indications in key international markets (2026-2027)
- •Mid-stage clinical trial readouts for innovative therapies (e.g., ADCs in oncology, next-gen immunology assets)
- •Potential strategic partnerships or bolt-on acquisitions to bolster pipeline
Long-Term (18+ months)
- •Sustained growth of non-Humira immunology portfolio (Skyrizi, Rinvoq) replacing Humira revenue
- •Successful commercialization of promising neuroscience (e.g., Alzheimer's, Parkinson's) and oncology assets entering late-stage development
- •Diversification into new therapeutic areas through R&D and M&A
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ABBV Bull Case: What Could Go Right
- ✓
Acceleration in revenue growth for Skyrizi and Rinvoq surpassing analyst expectations
- ✓
Positive clinical trial readouts for late-stage pipeline assets, particularly in neuroscience or next-gen oncology
- ✓
Consistent dividend increases and prudent capital allocation decisions
Bull Case Analysis
See what could go right with Premium
Never miss a move on ABBV
Create a free account to set price alerts and get notified on Telegram when ABBV hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for AbbVie Inc (ABBV)?
As of February 27, 2026, AbbVie Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of AbbVie Inc?
AbbVie Inc's market capitalization is approximately $403.8B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does AbbVie Inc use?
ABBV is the ticker symbol for AbbVie Inc. The company trades on the NYQ.
What is the risk level for ABBV stock?
Our analysis rates AbbVie Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABBV?
AbbVie Inc currently has a price-to-earnings (P/E) ratio of 171.8. This is above the market average, suggesting the stock may be priced for high growth expectations.
Does AbbVie Inc pay a dividend?
Yes, AbbVie Inc pays a dividend with a current yield of approximately 303.00%.
How often is the ABBV DVR analysis updated?
Our AI-powered analysis of AbbVie Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 27, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.